

IN THE CLAIMS

1. (original): A method of increasing the effective intracellular concentration of a therapeutic molecule within a cell expressing a P2X₇ receptor, the method comprising the step of contacting the cell with the therapeutic molecule and with a substance which modulates the P2X₇ receptor.
2. (original): A method according to claim 1, wherein the method comprises the step of contacting the cell with the therapeutic molecule and with a substance which stimulates the P2X₇ receptor.
3. (original): A method according to claim 1 or 2, wherein the therapeutic molecule is a cytotoxic drug and it is desired to kill the cell.
4. (currently amended): A method according to ~~any one of the preceding claims~~ claim 1, wherein the P2X₇ receptor modulating substance comprises ATP, an analogue of ATP, or an immunoglobulin or immunoglobulin-like variant which possesses specific binding activity for the P2X₇ receptor.
5. (currently amended): A method according to ~~any one of the preceding claims~~, claim 1 wherein the cell expresses an efflux protein which is inhibited by stimulation of the P2X₇ receptor.
6. (original): A method according to claim 5, wherein the efflux protein which is inhibited is one or more selected from the group consisting of: P-glycoprotein; mitoxantrone resistance protein; and a member of the multidrug-resistance associated family of proteins.
7. (currently amended): A method according to ~~any one of the preceding claims~~ claim 1, wherein the therapeutic molecule and the P2X₇ receptor modulating substance are co-administered.

8. (currently amended): A method according to ~~any one of the preceding claims~~ claim 1, wherein the cell is contacted with a substance which inhibits the activity and/or expression of CD45.

9. (currently amended): An *in vitro* method in accordance with ~~any of the preceding claims~~ claim 1.

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (original): A pharmaceutical composition for administration to a mammalian subject, the composition comprising: a therapeutic drug; a P2X₇ receptor modulating substance; and a physiologically acceptable carrier, diluent or excipient.

15. (original): A pharmaceutical composition in accordance with claim 14, the composition comprising: a therapeutic drug; a P2X₇ receptor stimulating substance; and a physiologically acceptable carrier, diluent or excipient.

16. (original): A pharmaceutical composition according to claim 14 or 15, further comprising a substance which inhibits the activity and/or expression of CD45.

17. (original): A method of making a pharmaceutical composition comprising the step of combining in a mixture a therapeutic drug, a P2X₇ receptor modulating substance, and a physiologically acceptable carrier, diluent or excipient.

18. (original): A method of making a pharmaceutical composition in accordance with claim 17, the method comprising the step of combining in a mixture a therapeutic drug, a P2X₇ receptor stimulating substance, and a physiologically acceptable carrier diluent or excipient.

19. (currently amended): A method according to claim 17 or 18, ~~comprising further combining the ingredients recited in claim 17 or 18 with~~ including a substance which inhibits the activity and/or expression of CD45.

20. (original): A method of inhibiting the action of a cell membrane efflux protein, the method comprising the step of contacting a cell expressing a P2X₇ receptor with a substance which causes activation of the P2X₇ receptor.

21. (original): An *in vitro* method of inhibiting the action of a cell membrane efflux protein in accordance with claim 20.

22. (new): A method of rearranging at least part of the lipid, phospholipid or glycolipid component of a cell membrane which comprises contacting said cell membrane with a P2X₇ receptor modulating substance.